CFT8634
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Synovial Sarcoma
Conditions
Synovial Sarcoma, Soft Tissue Sarcoma
Trial Timeline
Mar 25, 2022 → Dec 19, 2023
NCT ID
NCT05355753About CFT8634
CFT8634 is a phase 1 stage product being developed by C4 Therapeutics for Synovial Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05355753. Target conditions include Synovial Sarcoma, Soft Tissue Sarcoma.
What happened to similar drugs?
1 of 4 similar drugs in Synovial Sarcoma were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05355753 | Phase 1 | Terminated |
Competing Products
8 competing products in Synovial Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 2 | 39 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 44 |
| Pexidartinib | Daiichi Sankyo | Approved | 43 |
| Ramucirumab + Gemcitabine + Docetaxel | Eli Lilly | Phase 1/2 | 24 |
| LV305 + G305 | Merck | Phase 3 | 32 |
| TBI-1301 + Cyclophosphamide | Takara Bio | Phase 1/2 | 32 |
| TBI-1301 + Cyclophosphamide + Fludarabine | Takara Bio | Phase 3 | 47 |
| FHD-609 | Foghorn Therapeutics | Phase 1 | 11 |